We showed that supplementing the current standard-of-care combination of the BRAF inhibitor encorafenib plus an anti-EGFR antibody (panitumumab) with the FDA-approved COX2 inhibitor celecoxib significantly and consistently improved tumor growth inhibition. Here, EGFR is linked to neoplasm.